by barry-jtcir | Sep 4, 2024 | Press Releases
LA JOLLA, CA, Sept. 04, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and...
by barry-jtcir | Aug 14, 2024 | Press Releases
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and topline data on track for Q1 2025 LA JOLLA, CA, Aug. 14, 2024 — GRI...
by barry-jtcir | Jul 15, 2024 | Press Releases
Live video webcast on Wednesday, July 17th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative...
by barry-jtcir | Jul 11, 2024 | Press Releases
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) LA JOLLA, CA, July 11, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,”...
by barry-jtcir | Jul 8, 2024 | Press Releases
LA JOLLA, CA, July 08, 2024 — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and...
by barry-jtcir | Jul 2, 2024 | Press Releases
Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in mice Compared to controls, mice treated with GRI-0621 showed histological...
